文献速递泌尿生殖MR

实测多点超高b值扩散MRI评估MRI检出前列腺病变

Measured Multipoint Ultra-High b-Value Diffusion MRI in the Assessment of MRI-Detected Prostate Lesions.
PubMed 文献 · Invest Radiol · 2021-01-01

纳入73例接受3T前列腺MRI(含b=50/500/1000/1500 s/mm²及b=100/500/1000/1500/2250/3000/4000 s/mm²扩散加权成像)的患者,对50例的64个MRI检出病变行靶向经直肠超声/MRI融合穿刺,比较超高b值扩散参数与标准临床ADC(SD-ADC-2b-1000、SD-ADC-2b-1500)预测临床显著前列腺癌(Gleason分级组≥2)的效能;结果显示SD-ADC-2b-1000与SD-ADC-2b-1500效能无统计学差异(P=0.99),19个超高b值参数模型均未优于SD-ADC-2b-1500(所有P>0.05),决策曲线分析在3%~20%阈值概率区间未见更高净获益,未减少需活检的MRI病变。

要点

  • SD-ADC-2b-1000与SD-ADC-2b-1500预测临床显著前列腺癌的AUC均为0.82,两者无统计学差异(P=0.99)。
  • 19个含多点或2点超高b值ADC、Dapp、Kapp的logistic回归参数模型均未优于SD-ADC-2b-1500(所有P>0.05)。
  • 决策曲线分析在3%~20%癌症阈值概率区间未见超高b值参数较SD-ADC-2b-1500有更高净获益,且未减少需活检的MRI病变。

临床应用与阅片要点

  • 作者结论提示扩散MRI的大部分诊断获益已体现在由一个低b值和一个1000至1500 s/mm² b值组成的ADC中。
  • 与SD-ADC-2b-1500相比,超高b值参数在3%~20%癌症阈值概率区间未见更高净获益,且未减少需活检的MRI病变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of this study was to assess quantitative ultra-high b-value (UHB) diffusion magnetic resonance imaging (MRI)-derived parameters in comparison to standard clinical apparent diffusion coefficient (SD-ADC-2b-1000, SD-ADC-2b-1500) for the prediction of clinically significant prostate cancer, defined as Gleason Grade Group greater than or equal to 2.

MATERIALS AND METHODS: Seventy-three patients who underwent 3-T prostate MRI with diffusion-weighted imaging acquired at b = 50/500/1000/1500s/mm2 and b = 100/500/1000/1500/2250/3000/4000 s/mm2 were included. Magnetic resonance lesions were segmented manually on individual sequences, then matched to targeted transrectal ultrasonography/MRI fusion biopsies. Monoexponential 2-point and multipoint fits of standard diffusion and of UHB diffusion were calculated with incremental b-values. Furthermore, a kurtosis fit with parameters Dapp and Kapp with incremental b-values was obtained. Each parameter was examined for prediction of clinically significant prostate cancer using bootstrapped receiver operating characteristics and decision curve analysis. Parameter models were compared using Vuong test.

RESULTS: Fifty of 73 men (age, 66 years [interquartile range, 61-72]; prostate-specific antigen, 6.6 ng/mL [interquartile range, 5-9.7]) had 64 MRI-detected lesions. The performance of SD-ADC-2b-1000 (area under the curve, 0.82) and SD-ADC-2b-1500 (area under the curve, 0.82) was not statistically different (P = 0.99), with SD-ADC-2b-1500 selected as reference. Compared with the reference model, none of the 19 tested logistic regression parameter models including multipoint and 2-point UHB-ADC, Dapp, and Kapp with incremental b-values of up to 4000 s/mm2 outperformed SD-ADC-2b-1500 (all P's > 0.05). Decision curve analysis confirmed these results indicating no higher net benefit for UHB parameters in comparison to SD-ADC-2b-1500 in the clinically important range from 3% to 20% of cancer threshold probability. Net reduction analysis showed no reduction of MR lesions requiring biopsy.

CONCLUSIONS: Despite evaluation of a large b-value range and inclusion of 2-point, multipoint, and kurtosis models, none of the parameters provided better predictive performance than standard 2-point ADC measurements using b-values 50/1000 or 50/1500. Our results suggest that most of the diagnostic benefits available in diffusion MRI are already represented in an ADC composed of one low and one 1000 to 1500 s/mm2 b-value.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Tavakoli AA, Kuder TA, Tichy D, et al. Measured Multipoint Ultra-High b-Value Diffusion MRI in the Assessment of MRI-Detected Prostate Lesions. Invest Radiol. 2021. PMID: 32930560. doi:10.1097/RLI.0000000000000712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。